| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |


*University of Toronto, Toronto, Canada; and
Harvard School of Public Health, Boston, Massachusetts.
Correspondence to Dr, Charmaine E. Lok, Department of Medicine, Division of Nephrology, The Toronto General Hospital, 11 EN-216, 200 Elizabeth Street, Toronto, Ontario, M5G 2C4, Canada. Phone: 416-340-4140; Fax: 416-586-9827;
ABSTRACT. Hemodialysis patients in whom permanent vascular access cannot be achieved are dependent on a central venous catheter. In such patients, catheter-related infections are a common and serious complication. This study was a randomized clinical trial to determine if topical Polysporin Triple antibiotic ointment applied to the central venous catheter insertion site could reduce the incidence of catheter-related infections. A total of 169 patients receiving hemodialysis through a central venous catheter were randomized to receive Polysporin Triple or placebo using a double-blind study design. In the 6-mo study period, infections were observed in more patients in the placebo group than in the Polysporin Triple group (34 versus 12%; relative risk, 0.35; 95% CI, 0.18 to 0.68; P = 0.0013). The number of infections per 1000 catheter days (4.10 versus 1.02; P < 0.0001) and the number of bacteremias per 1000 catheter days (2.48 versus 0.63; P = 0.0004) were also greater in the placebo group. Within the 6-mo study period, there were 13 deaths in the placebo group as compared with 3 deaths in the Polysporin Triple group (P = 0.0041). When all available follow-up information was included, the difference in survival remained significant (19 versus 9 deaths; P = 0.0027). Within the first 6 mo, infections were observed in 7 of the 13 placebo subjects who died (54%) as compared with no infections in the three Polysporin Triple subjects who died. The prophylactic application of topical Polysporin Triple antibiotic ointment to the central venous catheter insertion site reduced the rate of infections and was associated with improved survival in hemodialysis patients. E-mail: charmaine.lok@uhn.on.ca
This article has been cited by other articles:
![]() |
M. T. James, J. Conley, M. Tonelli, B. J. Manns, J. MacRae, B. R. Hemmelgarn, and for the Alberta Kidney Disease Network Meta-analysis: Antibiotics for Prophylaxis against Hemodialysis Catheter-Related Infections Ann Intern Med, April 15, 2008; 148(8): 596 - 605. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. X. Garg, T. Greene, and N. W. Levin A well-conducted randomized trial that establishes no benefit of therapy is an important medical advance Nephrol. Dial. Transplant., January 1, 2008; 23(1): 52 - 55. [Full Text] [PDF] |
||||
![]() |
A. J. Bleyer Use of Antimicrobial Catheter Lock Solutions to Prevent Catheter-Related Bacteremia Clin. J. Am. Soc. Nephrol., September 1, 2007; 2(5): 1073 - 1078. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E. Lok, D. Appleton, C. Bhola, B. Khoo, and R. M. A. Richardson Trisodium citrate 4%--an alternative to heparin capping of haemodialysis catheters Nephrol. Dial. Transplant., February 1, 2007; 22(2): 477 - 483. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Jindal, C. T. Chan, C. Deziel, D. Hirsch, S. D. Soroka, M. Tonelli, and B. F. Culleton CHAPTER 4: Vascular Access J. Am. Soc. Nephrol., March 1, 2006; 17(3_suppl_1): S16 - S23. [Full Text] [PDF] |
||||
![]() |
R. N. Foley, H. Guo, J. J. Snyder, D. T. Gilbertson, and A. J. Collins Septicemia in the United States Dialysis Population, 1991 to 1999 J. Am. Soc. Nephrol., April 1, 2004; 15(4): 1038 - 1045. [Abstract] [Full Text] [PDF] |
||||
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |
Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673